:’
Recent clinical trial data from ALX Oncology Holdings Inc. has illuminated the potential of evorpacept, a next-generation CD47 blocker, in treating various forms of cancer. This article outlines the findings from three distinct clinical studies involving HER2-positive gastric cancer, human papillomavirus-mediated oropharyngeal cancer, and relapsed or refractory B-cell non-Hodgkin lymphoma, highlighting the efficacy, safety, and innovative approaches that involve combining evorpacept with established treatments.
ALX Oncology Holdings Inc. has garnered attention in the field of immuno-oncology with its investigational therapy, evorpacept, aimed at inhibiting the CD47 immune checkpoint pathway. With a focus on enhancing the immune system’s ability to combat cancer, the company has reported promising results from multiple clinical trials, underscoring evorpacept’s potential in treating a variety of malignancies.
ASPEN-06 Phase 2 Trial Results:’
On July 31, 2024, ALX Oncology released topline results from its ASPEN-06 Phase 2 clinical trial targeting HER2-positive advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial evaluated patients with previously treated conditions, demonstrating significant improvements in the overall response rate (ORR) and duration of response (DoR) following treatment with evorpacept. These results are particularly noteworthy as they exhibit the potential for evorpacept to enhance tumor response rates, thereby providing a new avenue of hope for patients with limited treatment options in advanced stages of this disease.
Initiation of Phase 2 Trial for HPV-Mediated Oropharyngeal Cancer:’
Continuing its clinical research, ALX Oncology announced on April 30, 2024, the initiation of a Phase 2 investigator-sponsored trial (IST) combining neoadjuvant radiation with evorpacept and pembrolizumab (KEYTRUDA) for patients with untreated HPV-mediated oropharyngeal cancer. Conducted by Dr. Joseph A. Califano III at UC San Diego, this trial aims to evaluate the safety and efficacy of this combination therapy in a multi-center, single-arm setting. Such innovative approaches utilizing evorpacept alongside standard therapies reflect a growing trend in precision oncology.
Phase 1/2 Clinical Trial in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma:’
In an ongoing Phase 1/2 clinical trial involving patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), evorpacept showed encouraging initial activity when combined with standard-of-care therapy, including rituximab and lenalidomide (R²). In a cohort of twenty patients, the combination displayed a remarkable overall response rate of 94%, coupled with a complete response rate of 83%significantly higher than the historical CRR benchmark of 34% for R². Furthermore, the combination therapy exhibited a safety profile comparable to previous R² therapies, suggesting a favorable tolerability for patients.
Conclusion:’
The recent clinical data released by ALX Oncology presents evorpacept as a compelling candidate for enhancing therapeutic outcomes across multiple cancer types. The impressive response rates observed in advanced gastric cancer, oropharyngeal cancer, and relapsed or refractory B-cell non-Hodgkin lymphoma underscore the potential of evorpacept in revolutionizing the treatment landscape. Continued research and clinical validation will be essential in determining the broader implications of evorpacept as part of integrated cancer treatment strategies.
Keywords:’ Evorpacept, CD47 blockade, HER2-positive gastric cancer, HPV-mediated oropharyngeal cancer, non-Hodgkin lymphoma, immunotherapy, clinical trial.
Comments